Friday, 2 October 2026Updated 5m ago
← Top stories
Expansion▲ Bullish for Zydus Lifesciences

New launches, chronic portfolio to maintain growth for Zydus Lifesciences

1 source · first seen 14:53 2 Oct · updated 14:53 2 Oct

The brief

Written from 1 report · check the source before you trade
  • Domestic formulations, chronic therapies and US launches have supported Zydus Lifesciences’ growth and rally
  • Valuations now stand above…
  • Growth supports Zydus Lifesciences, though elevated valuations may limit further gains

Tags on this story

Pick a tag to see all its stories
Zydus Lifesciences₹1,145.70 · 2 todayPharma and healthcare15 todayMarket valuations18 today

Linked by the tag Zydus Lifesciences

14 stories this week
  1. 29 SeptZydus hits 52-week high, can the optimism continue?Market move · 1 source · Zydus Lifesciences has gained 32% in 2026
  2. 28 SeptZydus Life USFDA inspection at Ahmedabad plant concludes with 1 observation2 sources · The Ahmedabad plant inspection concluded with one observation; Zydus said there were no data integrity-related observations
  3. 26 SeptZydus Lifesciences’ New Jersey office clears USFDA inspection with no observations2 sources · USFDA inspection concluded with nil observations
  4. 25 SeptIndian stock market slides, but 28 Nifty 500 stocks hit fresh 1-year highs this week; MCX, PVR Inox among themMarket move · 1 source · Nifty 50 fell 0.88% over the week, its biggest decline since 2020
All Zydus Lifesciences stories →

Read the reports

1 report · earliest 14:53
Business StandardNew launches, chronic portfolio to maintain growth for Zydus Lifesciences14:53